TickerHumNYSE · Healthcare · Drug Manufacturers—General
Merck & Co., Inc. (MRK)
As of Nov 11, 1:50 PM ET, Merck & Co. (MRK) last traded at $146.45, down 1.08% on the day. Its TickerHum research score is 49/100 (average). It reported revenue of $67.38B for the twelve months ending 2026-09-30, up 4.9% year over year.
Ratings
- Valuation: 46/100 — Strongest input: price / sales (ttm) 5.3x. Weakest: price / earnings (ttm) 147.3x.
- Growth: 19/100 — Strongest input: revenue growth (ttm, yoy) +4.9 %. Weakest: diluted eps growth (ttm, yoy) -86.9 %.
- Profitability: 32/100 — Strongest input: net margin 3.6 %. Weakest: return on equity 5.5 %.
- Financial health: 34/100 — Strongest input: long-term debt / equity 1.11. Weakest: cash / long-term debt 0.19.
- Momentum: 82/100 — Strongest input: 1-year return +59.5 %. Weakest: 3-month return +7.6 %.
- Attention: 50/100 — Strongest input: headlines in the last 7 days 28. Weakest: volume vs 3-month average 0.2x.
- Risk resilience: 83/100 — Strongest input: max drawdown (1y) -11.9 %. Weakest: annualised volatility (1y) 29.6 %.
- Data confidence: 97/100 — Strongest input: quote age (hours) 0 h. Weakest: inputs available 90 %.
Reported fundamentals
| Metric | Value | Period |
|---|---|---|
| Revenue | $67.38B | TTM ending 2026-09-30 · 10-Q |
| Revenue growth | 4.9% | TTM ending 2026-09-30 · 10-Q |
| Net income | $2.45B | TTM ending 2026-09-30 · 10-Q |
| Diluted EPS | $0.99 | TTM ending 2026-09-30 · 10-Q |
| Net margin | 3.6% | TTM ending 2026-09-30 · 10-Q |
| Free cash flow | $14.75B | TTM ending 2026-09-30 · 10-Q |
| Cash | $9.55B | as of 2026-09-30 · 10-Q |
| Long-term debt | $49.69B | as of 2026-09-30 · 10-Q |
| Debt / equity | 1.11 | as of 2026-09-30 · 10-Q |
Source: SEC EDGAR XBRL company facts (CIK 0000310158).
Comparable companies for Merck & Co.
Selected by industry, business overlap and scale; these are not necessarily direct competitors.
- Merck & Co. vs Pfizer (MRK vs PFE) — Same industry (Drug Manufacturers—General); market cap 0.46x; shares: oncology, vaccines
- Merck & Co. vs AbbVie (MRK vs ABBV) — Same industry (Drug Manufacturers—General); market cap 1.4x; shares: oncology
- Merck & Co. vs Amgen (MRK vs AMGN) — Same industry (Drug Manufacturers—General); market cap 0.69x; shares: oncology
- Merck & Co. vs Gilead Sciences (MRK vs GILD) — Same industry (Drug Manufacturers—General); market cap 0.58x; shares: oncology
- Merck & Co. vs Bristol-Myers Squibb (MRK vs BMY) — Same industry (Drug Manufacturers—General); market cap 0.35x; shares: oncology
Prices: Yahoo Finance (public) — Free public Yahoo Finance data. Prices may be delayed and are for information only.